Scholar Rock Holding (SRRK) Change in Account Payables (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Change in Account Payables came in at -$1.1 million in Q1 2026, up 80.82% year-on-year from -$600032.3 in Q1 2025, and down 130.66% quarter-over-quarter from $3.5 million in Q4 2025.
Scholar Rock Holding (SRRK) Change in Account Payables (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Change in Account Payables history runs 10 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 80.82% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 202.21% increase from a year earlier, with the FY2025 full-year figure at $208000.0, down 96.86% from the prior year.
- Change in Account Payables retreated to -$1.1 million in Q1 2026 per SRRK's latest filing, from $3.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.0 million in Q4 2024 and bottomed at -$5.7 million in Q1 2025.
- The 5-year median for Change in Account Payables is -$274000.0 (2023), against an average of $292529.4.
- Biggest YoY gain for Change in Account Payables was 648.68% in 2025; the steepest drop was 827.54% in 2025.
- Year by year, Change in Account Payables stood at $2.0 million in 2022, then dropped by 24.92% to $1.5 million in 2023, then surged by 302.4% to $6.0 million in 2024, then slumped by 41.25% to $3.5 million in 2025, then sank by 130.66% to -$1.1 million in 2026.
- Per Business Quant, the three latest SRRK Change in Account Payables figures stand at -$1.1 million (Q1 2026), $3.5 million (Q4 2025), and $5.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | -1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.09 Mn |
| Mar 31, 2026 | -1.09 Mn |
| Dec 31, 2025 | 3.54 Mn |
| Dec 31, 2025 | 3.54 Mn |
| Sep 30, 2025 | 5.66 Mn |
| Sep 30, 2025 | 5.66 Mn |
| Jun 30, 2025 | -3.33 Mn |
| Jun 30, 2025 | -3.33 Mn |
| Mar 31, 2025 | -5.66 Mn |
| Mar 31, 2025 | -5.66 Mn |
| Dec 31, 2024 | 6.02 Mn |
| Dec 31, 2024 | 6.02 Mn |
| Sep 30, 2024 | 756,000.00 |
| Sep 30, 2024 | 756,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Mar 31, 2024 | -610,000.00 |
| Mar 31, 2024 | -610,000.00 |
| Dec 31, 2023 | 1.50 Mn |
| Dec 31, 2023 | 1.50 Mn |